Chinese and foreign pharmaceutical companies are strongly aiming at the generic drug market
Release time: 2011-09-08 & nbsp & nbsp & nbsp Source:
Business Club, September 7th News Since the second half of this year，Chinese and Foreign Pharmaceutical Company frequently strong joint，Common domestic development、The trend of the international generic drug market has become more and more obvious。
Jizheng Pharmaceutical and American Pharmaceutical Giant Pfizer Pharmaceutical、Since the establishment of a joint venture with the US Merck Company，September 6，Fosun Pharmaceutical and Swiss Longsha Group established a joint venture in Shanghai，Aimed at the urgent need of high -tech barriers to be urgently needed in the Chinese market。
Marketing person said，Cooperation of multinational enterprises and local enterprises，Not only will it help improve the level of the domestic generic drug industry，It will also promote Chinese pharmaceutical companies to achieve industrial upgrading，and accelerate internationalization。
The imitation drug market is favored
Benefiting from the rapid growth of China's economy and new medical reform，The Chinese pharmaceutical Stake Sports BettingStake Sports Bettingmarket will usher in the ten years of rapid growth。According to IMS estimates，China will become the world's second largest pharmaceutical market in about 2020。At the same time，Many drug patents expire，It is a good time for Chinese pharmaceutical companies to enter the generic drug market。According to the person from the Chinese Medical Insurance Chamber of Commerce，2011-2015 will lose patent protection at $ 77 billion in medicines around the world。For example，2010，The antidepressant produced by Pfizer Effexor patent expires，This medicine has set a record of $ 3.8 billion a year; the company's number one product -cholesterol drug, which will expire in November 2011，In the sales of Pfizer 67.8 billion US dollars in 2010，Lipur's sales account for $ 10.7 billion。These drug patents expire will bring tremendous pressure on the prospects of the European and American pharmaceutical giants，But for many domestic pharmaceutical companies, it means huge market opportunities。
For this，Li Xianlin, senior vice president of Fosun Pharmaceutical, told reporters，Most of the global patent drugs belong to all the multinational pharmaceutical companies，These drugs are usually high in price。So，Fosun Pharmaceuticals look forward to through international cooperation，High -end medicine with a more reasonable development price，Grasp market opportunities。
Swiss Longsha Group has more than 100 years of professional pharmaceutical experience，It is a global technology and large -scale raw and drug research and development and customer custom enterprise，In small molecules、polypeptide、The research and development and production process of pharmaceutical core technology in different fields in different fields is in the world's leading position。According to Harry But, a member of the Management Committee of the Swiss Longsha Group, Stake Sports Bettingstake betting apprevealed to reporters，will cooperate with Fosun Pharmaceutical，Enter the generic drug market through small molecular drugs。
It is reported，The first phase of the two parties invested 100 million yuan，The ratio of their respective capital is 50%: 50%，The drugs developed in the early stage are mainly for anti -tumor、Anti -infection and cardiovascular treatment fields。The target of the joint venture is to become China's leading generic drug company in 2020，Provide high -end drugs to the market and can bear in terms of price。
Harry Bott points out，At present, China accounts for less than 2%in the global pharmaceutical market，With the growth of the Chinese pharmaceutical market，China will soon become the world's largest pharmaceutical market。At the same time，Although China is also expected to become one of the world's largest pharmaceutical production sites，But only a few companies currently use the latest technology to produce high -end drugs，Therefore, international cooperation has great potential to discover。
Luo Jiali, Vice President of Haizheng Pharmaceutical Business Development, who cooperated with the American Pharmaceutical Giant Pfizer Pharmaceutical, told reporters，Through a strategic partner of becoming a large international pharmaceutical company，Can further consolidate the leading advantage of technology。According to the "Twelfth Five -Year" development planning target of Hai Zheng Pharmaceutical，The company will accelerate from raw medicine to preparation、Extension from the domestic market to the international market，Transition to global imitation drug brand enterprises。
According to the relevant person in a listed company in Zhejiang, a listed company in Zhejiang，The company is also negotiating joint ventures with pharmaceutical companies such as Sanofei，Plan to cooperate in generic stake online sports bettingstake betting appdrugs。"After the patent expires，Who can achieve imitation sooner，The higher the level of profitability of who is。"The person said。
Chinese pharmaceutical company test water internationalization
From the current situation，The international cooperation model between pharmaceutical companies is gradually being accepted by the market。
Some brokerage researcher believes，Cooperation between Hyegy Pharmaceutical and Pfizer Pharmaceutical，It is expected to add points to its performance this year。According to an introduction，Haizheng Pharmaceutical has been in good cooperation with the United States Lilly Company (curl molds and other projects) and Xianlingya (Elsecin and other projects)，Earlier ELANCO was announced at the beginning of this year、Long -term cooperation agreement of Pfizer Pharmaceutical Veterinary Pharmaceutical Health Products。"Currently signed a long -term comprehensive cooperation agreement with Pfizer Pharmaceutical，It means that the company is further deepening international cooperation，It will be likely to accept more international transfer production orders。"The researcher said this。
strong innovative ability and brand、High comprehensive quality of marketing is considered by foreign companies when choosing domestic partners。Fosun Pharmaceuticals has continued to invest in innovation over the years，Established a R & D system combined with imitation，Focus on cardiovascular、metabolism、Anti -infection、Anti -tumor and other key areas，and formed a certain advantage in these fields。
According to Vice Chairman of Fosun Group、CEO Liang Xinjun introduced to reporters，As the leading pharmaceutical company in China，Fosun Pharmaceutical will seize the opportunity to imitate pharmaceuticals，Efforts to enhance the international competitiveness of the stake online sports bettingstake betting appcompany，Dedicated to make the company into an international enterprise。
Internationalization is already the development direction of China's leading pharmaceutical companies。Data of the Data of the Medical Insurance Chamber of Commerce，At present, the production lines of 24 domestic companies have passed the European and American certification，More and more domestic pharmaceutical companies will go to the international stage。
Of course，The road of internationalization is not flat。From the perspective of Luo Jiali，At present, domestic enterprises only stay in the stage of establishing production lines and applying for new drug applications，These are just the beginning of the exit of the preparation，The real internationalization should include overseas channel expansion、System engineering, which is maintained by its own brand。(Royal)
Jizheng Pharmaceutical and American Pharmaceutical Giant Pfizer Pharmaceutical、Since the establishment of a joint venture with the US Merck Company，September 6，Fosun Pharmaceutical and Swiss Longsha Group established a joint venture in Shanghai，Aimed at the urgent need of high -tech barriers to be urgently needed in the Chinese market。
Marketing person said，Cooperation of multinational enterprises and local enterprises，Not only will it help improve the level of the domestic generic drug industry，It will also promote Chinese pharmaceutical companies to achieve industrial upgrading，and accelerate internationalization。
The imitation drug market is favored
Benefiting from the rapid growth of China's economy and new medical reform，The Chinese pharmaceutical Stake Sports BettingStake Sports Bettingmarket will usher in the ten years of rapid growth。According to IMS estimates，China will become the world's second largest pharmaceutical market in about 2020。At the same time，Many drug patents expire，It is a good time for Chinese pharmaceutical companies to enter the generic drug market。According to the person from the Chinese Medical Insurance Chamber of Commerce，2011-2015 will lose patent protection at $ 77 billion in medicines around the world。For example，2010，The antidepressant produced by Pfizer Effexor patent expires，This medicine has set a record of $ 3.8 billion a year; the company's number one product -cholesterol drug, which will expire in November 2011，In the sales of Pfizer 67.8 billion US dollars in 2010，Lipur's sales account for $ 10.7 billion。These drug patents expire will bring tremendous pressure on the prospects of the European and American pharmaceutical giants，But for many domestic pharmaceutical companies, it means huge market opportunities。
For this，Li Xianlin, senior vice president of Fosun Pharmaceutical, told reporters，Most of the global patent drugs belong to all the multinational pharmaceutical companies，These drugs are usually high in price。So，Fosun Pharmaceuticals look forward to through international cooperation，High -end medicine with a more reasonable development price，Grasp market opportunities。
Swiss Longsha Group has more than 100 years of professional pharmaceutical experience，It is a global technology and large -scale raw and drug research and development and customer custom enterprise，In small molecules、polypeptide、The research and development and production process of pharmaceutical core technology in different fields in different fields is in the world's leading position。According to Harry But, a member of the Management Committee of the Swiss Longsha Group, Stake Sports Bettingstake betting apprevealed to reporters，will cooperate with Fosun Pharmaceutical，Enter the generic drug market through small molecular drugs。
It is reported，The first phase of the two parties invested 100 million yuan，The ratio of their respective capital is 50%: 50%，The drugs developed in the early stage are mainly for anti -tumor、Anti -infection and cardiovascular treatment fields。The target of the joint venture is to become China's leading generic drug company in 2020，Provide high -end drugs to the market and can bear in terms of price。
Harry Bott points out，At present, China accounts for less than 2%in the global pharmaceutical market，With the growth of the Chinese pharmaceutical market，China will soon become the world's largest pharmaceutical market。At the same time，Although China is also expected to become one of the world's largest pharmaceutical production sites，But only a few companies currently use the latest technology to produce high -end drugs，Therefore, international cooperation has great potential to discover。
Luo Jiali, Vice President of Haizheng Pharmaceutical Business Development, who cooperated with the American Pharmaceutical Giant Pfizer Pharmaceutical, told reporters，Through a strategic partner of becoming a large international pharmaceutical company，Can further consolidate the leading advantage of technology。According to the "Twelfth Five -Year" development planning target of Hai Zheng Pharmaceutical，The company will accelerate from raw medicine to preparation、Extension from the domestic market to the international market，Transition to global imitation drug brand enterprises。
According to the relevant person in a listed company in Zhejiang, a listed company in Zhejiang，The company is also negotiating joint ventures with pharmaceutical companies such as Sanofei，Plan to cooperate in generic stake online sports bettingstake betting appdrugs。"After the patent expires，Who can achieve imitation sooner，The higher the level of profitability of who is。"The person said。
Chinese pharmaceutical company test water internationalization
From the current situation，The international cooperation model between pharmaceutical companies is gradually being accepted by the market。
Some brokerage researcher believes，Cooperation between Hyegy Pharmaceutical and Pfizer Pharmaceutical，It is expected to add points to its performance this year。According to an introduction，Haizheng Pharmaceutical has been in good cooperation with the United States Lilly Company (curl molds and other projects) and Xianlingya (Elsecin and other projects)，Earlier ELANCO was announced at the beginning of this year、Long -term cooperation agreement of Pfizer Pharmaceutical Veterinary Pharmaceutical Health Products。"Currently signed a long -term comprehensive cooperation agreement with Pfizer Pharmaceutical，It means that the company is further deepening international cooperation，It will be likely to accept more international transfer production orders。"The researcher said this。
strong innovative ability and brand、High comprehensive quality of marketing is considered by foreign companies when choosing domestic partners。Fosun Pharmaceuticals has continued to invest in innovation over the years，Established a R & D system combined with imitation，Focus on cardiovascular、metabolism、Anti -infection、Anti -tumor and other key areas，and formed a certain advantage in these fields。
According to Vice Chairman of Fosun Group、CEO Liang Xinjun introduced to reporters，As the leading pharmaceutical company in China，Fosun Pharmaceutical will seize the opportunity to imitate pharmaceuticals，Efforts to enhance the international competitiveness of the stake online sports bettingstake betting appcompany，Dedicated to make the company into an international enterprise。
Internationalization is already the development direction of China's leading pharmaceutical companies。Data of the Data of the Medical Insurance Chamber of Commerce，At present, the production lines of 24 domestic companies have passed the European and American certification，More and more domestic pharmaceutical companies will go to the international stage。
Of course，The road of internationalization is not flat。From the perspective of Luo Jiali，At present, domestic enterprises only stay in the stage of establishing production lines and applying for new drug applications，These are just the beginning of the exit of the preparation，The real internationalization should include overseas channel expansion、System engineering, which is maintained by its own brand。(Royal)
